Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma

B. L. Dalkin, Frederick R Ahmann, J. B. Kopp

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

In their derivation of normal prostate specific antigen (PSA) levels (0 to 4.0 ng./ml.) Hybritech used almost exclusively men less than 60 years old. The purpose of this study was to define PSA levels by age decade in men older than 50 years without clinical evidence of prostatic carcinoma or so-called cancer-free. We define the cancer-free population as men with a PSA less than or equal to 4.0 ng./ml. and nonsuspicious digital rectal examination, and those with an abnormality in either parameter with a nonmalignant prostate biopsy. A total of 755 men was recruited for a prostate cancer detection study using serum PSA and digital rectal examination, of whom 728 fulfilled our criteria of cancer-free. Newly derived mean and standard deviation were 1.32 ± 1.10 ng./ml. in the 50 to 59-year group, 1.91 ± 1.72 ng./ml. in the 60 to 69-year group and 2.36 ± 1.98 ng./ml. in the 70 to 79-year group. The upper limits for PSA (mean + 2 standard deviations) by age were 3.5 ng./ml. in the 50 to 59-year group, 5.4 ng./ml. in the 60 to 69-year group and 6.3 ng./ml. in the 70 to 79-year group. The apparent accuracy of these new limits is strong in the 60 to 69-year group but it declines in the next decade. The data support further attempts at using PSA, age and digital rectal examination to establish selection criteria for prostate biopsy with adequate sensitivity and specificity.

Original languageEnglish (US)
Pages (from-to)1837-1839
Number of pages3
JournalJournal of Urology
Volume150
Issue number6
StatePublished - 1993

Fingerprint

Prostate-Specific Antigen
Carcinoma
Digital Rectal Examination
Prostate
Biopsy
Neoplasms
Patient Selection
Prostatic Neoplasms
Sensitivity and Specificity
Serum
Population

Keywords

  • antigens, neoplasm
  • prostate

ASJC Scopus subject areas

  • Urology

Cite this

Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. / Dalkin, B. L.; Ahmann, Frederick R; Kopp, J. B.

In: Journal of Urology, Vol. 150, No. 6, 1993, p. 1837-1839.

Research output: Contribution to journalArticle

@article{fc7af90e5c7e4eadab38e07b52c1617e,
title = "Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma",
abstract = "In their derivation of normal prostate specific antigen (PSA) levels (0 to 4.0 ng./ml.) Hybritech used almost exclusively men less than 60 years old. The purpose of this study was to define PSA levels by age decade in men older than 50 years without clinical evidence of prostatic carcinoma or so-called cancer-free. We define the cancer-free population as men with a PSA less than or equal to 4.0 ng./ml. and nonsuspicious digital rectal examination, and those with an abnormality in either parameter with a nonmalignant prostate biopsy. A total of 755 men was recruited for a prostate cancer detection study using serum PSA and digital rectal examination, of whom 728 fulfilled our criteria of cancer-free. Newly derived mean and standard deviation were 1.32 ± 1.10 ng./ml. in the 50 to 59-year group, 1.91 ± 1.72 ng./ml. in the 60 to 69-year group and 2.36 ± 1.98 ng./ml. in the 70 to 79-year group. The upper limits for PSA (mean + 2 standard deviations) by age were 3.5 ng./ml. in the 50 to 59-year group, 5.4 ng./ml. in the 60 to 69-year group and 6.3 ng./ml. in the 70 to 79-year group. The apparent accuracy of these new limits is strong in the 60 to 69-year group but it declines in the next decade. The data support further attempts at using PSA, age and digital rectal examination to establish selection criteria for prostate biopsy with adequate sensitivity and specificity.",
keywords = "antigens, neoplasm, prostate",
author = "Dalkin, {B. L.} and Ahmann, {Frederick R} and Kopp, {J. B.}",
year = "1993",
language = "English (US)",
volume = "150",
pages = "1837--1839",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma

AU - Dalkin, B. L.

AU - Ahmann, Frederick R

AU - Kopp, J. B.

PY - 1993

Y1 - 1993

N2 - In their derivation of normal prostate specific antigen (PSA) levels (0 to 4.0 ng./ml.) Hybritech used almost exclusively men less than 60 years old. The purpose of this study was to define PSA levels by age decade in men older than 50 years without clinical evidence of prostatic carcinoma or so-called cancer-free. We define the cancer-free population as men with a PSA less than or equal to 4.0 ng./ml. and nonsuspicious digital rectal examination, and those with an abnormality in either parameter with a nonmalignant prostate biopsy. A total of 755 men was recruited for a prostate cancer detection study using serum PSA and digital rectal examination, of whom 728 fulfilled our criteria of cancer-free. Newly derived mean and standard deviation were 1.32 ± 1.10 ng./ml. in the 50 to 59-year group, 1.91 ± 1.72 ng./ml. in the 60 to 69-year group and 2.36 ± 1.98 ng./ml. in the 70 to 79-year group. The upper limits for PSA (mean + 2 standard deviations) by age were 3.5 ng./ml. in the 50 to 59-year group, 5.4 ng./ml. in the 60 to 69-year group and 6.3 ng./ml. in the 70 to 79-year group. The apparent accuracy of these new limits is strong in the 60 to 69-year group but it declines in the next decade. The data support further attempts at using PSA, age and digital rectal examination to establish selection criteria for prostate biopsy with adequate sensitivity and specificity.

AB - In their derivation of normal prostate specific antigen (PSA) levels (0 to 4.0 ng./ml.) Hybritech used almost exclusively men less than 60 years old. The purpose of this study was to define PSA levels by age decade in men older than 50 years without clinical evidence of prostatic carcinoma or so-called cancer-free. We define the cancer-free population as men with a PSA less than or equal to 4.0 ng./ml. and nonsuspicious digital rectal examination, and those with an abnormality in either parameter with a nonmalignant prostate biopsy. A total of 755 men was recruited for a prostate cancer detection study using serum PSA and digital rectal examination, of whom 728 fulfilled our criteria of cancer-free. Newly derived mean and standard deviation were 1.32 ± 1.10 ng./ml. in the 50 to 59-year group, 1.91 ± 1.72 ng./ml. in the 60 to 69-year group and 2.36 ± 1.98 ng./ml. in the 70 to 79-year group. The upper limits for PSA (mean + 2 standard deviations) by age were 3.5 ng./ml. in the 50 to 59-year group, 5.4 ng./ml. in the 60 to 69-year group and 6.3 ng./ml. in the 70 to 79-year group. The apparent accuracy of these new limits is strong in the 60 to 69-year group but it declines in the next decade. The data support further attempts at using PSA, age and digital rectal examination to establish selection criteria for prostate biopsy with adequate sensitivity and specificity.

KW - antigens, neoplasm

KW - prostate

UR - http://www.scopus.com/inward/record.url?scp=0027740375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027740375&partnerID=8YFLogxK

M3 - Article

C2 - 7693980

AN - SCOPUS:0027740375

VL - 150

SP - 1837

EP - 1839

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -